Guggenheim Maintains Buy on Spyre Therapeutics, Raises Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Yatin Suneja has maintained a Buy rating on Spyre Therapeutics and raised the price target from $50 to $65.
October 25, 2024 | 7:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim has reaffirmed its Buy rating on Spyre Therapeutics and increased the price target to $65, indicating confidence in the company's future performance.
The increase in price target from $50 to $65 by Guggenheim suggests a positive outlook on Spyre Therapeutics' future performance. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100